Balancing repair and tolerance of DNA damage caused by alkylating agents

Nature Reviews Cancer

Volumn 12, Issue 2, 2012, Pages 104-120

  Fu, Dragony ^a   Calvo, Jennifer A ^a   Samson, Leona D ^a  

^a Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; AZIRIDINE DERIVATIVE; BENDAMUSTINE; CARMUSTINE; CHLORMETHINE; CHLORMETHINE DERIVATIVE; CYCLOPHOSPHAMIDE; DACARBAZINE; DNA; DNA GLYCOSYLTRANSFERASE; DNA METHYLTRANSFERASE; FOTEMUSTINE; LOMUSTINE; MELPHALAN; METHOXYAMINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MITOMYCIN C; NIMUSTINE; PROCARBAZINE; STREPTOZOCIN; TEMOZOLOMIDE; THIOTEPA;

CANCER CHEMOTHERAPY; CELL DEATH; CHEMOSENSITIVITY; CYTOTOXICITY; DNA ALKYLATION; DNA DAMAGE; DNA REPAIR; DNA STRAND BREAKAGE; DRUG TOLERANCE; EPIGENETICS; EXCISION REPAIR; GENE MUTATION; GENETICS; HUMAN; MISMATCH REPAIR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SISTER CHROMATID; SISTER CHROMATID EXCHANGE;

ALKYLATING AGENTS; BASE PAIR MISMATCH; DNA DAMAGE; DNA REPAIR; HUMANS;

EID: 84856233300     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc3185     Document Type: Review

References (209)

1. Ballschmiter, K. Pattern and sources of naturally produced organohalogens in the marine environment: biogenic formation of organohalogens. Chemosphere 52, 313-324 (2003). (Pubitemid 36612865)
2. Hecht, S. S. DNA adduct formation from tobacco-specific N-nitrosamines. Mutat. Res. 424, 127-142 (1999). (Pubitemid 29101614)
3. Hamilton, J. T., McRoberts, W. C., Keppler, F., Kalin, R. M. & Harper, D. B. Chloride methylation by plant pectin: an efficient environmentally significant process. Science 301, 206-209 (2003). (Pubitemid 36858471)
4. Rydberg, B. & Lindahl, T. Nonenzymatic methylation of DNA by the intracellular methyl group donor S-adenosyl-L-methionine is a potentially mutagenic reaction. EMBO J. 1, 211-216 (1982).
5. Taverna, P. & Sedgwick, B. Generation of an endogenous DNA-methylating agent by nitrosation in Escherichia coli. J. Bacteriol. 178, 5105-5111 (1996). (Pubitemid 26293067)
6. Bartsch, H., O'Neill, I. K., Schulte-Hermann, R. & International Agency for Research on Cancer. Relevance of N-Nitroso Compounds to Human Cancer: Exposures and Mechanisms (Oxford Univ. Press distributor, Lyon, London, 1987).
7. Kufe, D. W. et al. (eds) Cancer Medicine, 6th edn (BC Decker, Hamilton, Canada, 2003).
8. Shrivastav, N., Li, D. & Essigmann, J. M. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis 31, 59-70 (2010).
9. Drablos, F. et al. Alkylation damage in DNA and RNA-repair mechanisms and medical significance. DNA Repair 3, 1389-1407 (2004). (Pubitemid 39221738)
10. Johnson, R. E., Yu, S.-L., Prakash, S. & Prakash, L. A Role for yeast and human translesion synthesis DNA polymerases in promoting replication through 3-methyl adenine. Mol. Cell. Biol. 27, 7198-7205 (2007). (Pubitemid 47549755)
11. Engelward, B. P. et al. A chemical and genetic approach together define the biological consequences of 3-methyladenine lesions in the mammalian genome. J. Biol. Chem. 273, 5412-5418 (1998). (Pubitemid 28108711)
12. Gate, L. & Tew, K. D. in Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures (ed. Minev, B. R.) 61-85 (Springer Netherlands, 2011).
13. Sedgwick, B., Bates, P. A., Paik, J., Jacobs, S. C. & Lindahl, T. Repair of alkylated DNA: recent advances. DNA Repair 6, 429-442 (2007). (Pubitemid 46357047)
14. Samson, L., Thomale, J. & Rajewsky, M. F. Alternative pathways for the in vivo repair of O6-alkylguanine and O4-alkylthymine in Escherichia coli: the adaptive response and nucleotide excision repair. EMBO J. 7, 2261-2267 (1988).
15. Huang, J. C., Hsu, D. S., Kazantsev, A. & Sancar, A. Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. Proc. Natl Acad. Sci. USA 91, 12213-12217 (1994). (Pubitemid 24368635)
16. Hanawalt, P. Subpathways of nucleotide excision repair and their regulation. Oncogene 21, 8949-8956 (2002). (Pubitemid 36110824)
17. Kaina, B., Christmann, M., Naumann, S. & Roos, W. P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair 6, 1079-1099 (2007). (Pubitemid 47058389)
18. Deans, A. J. & West, S. C. DNA interstrand crosslink repair and cancer. Nature Rev. Cancer 11, 467-480 (2011).
19. Kee, Y. & D'Andrea, A. D. Expanded roles of the Fanconi anemia pathway in preserving genomic stability. Genes Dev. 24, 1680-1694 (2010).
20. Lange, S. S., Takata, K. & Wood, R. D. DNA polymerases and cancer. Nature Rev. Cancer 11, 96-110 (2011).
21. Svilar, D., Goellner, E. M., Almeida, K. H. & Sobol, R. W. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid. Redox Signal. 14, 2491-2507 (2011).
22. Monti, P. et al. Rev1 and Polzeta influence toxicity and mutagenicity of Me-lex, a sequence selective N3-adenine methylating agent. DNA Repair 7, 431-438 (2008).
23. Monti, P. et al. Mutagenicity of N3-methyladenine: a multi-translesion polymerase affair. Mutat. Res. 683, 50-56 (2010).
24. Roos, W. P. et al. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs. Mol. Pharmacol. 76, 927-934 (2009).
25. Prasad, R., Shock, D. D., Beard, W. A. & Wilson, S. H. Substrate channeling in mammalian base excision repair pathways: passing the baton. J. Biol. Chem. 285, 40479-40488 (2010).
26. Mol, C. D., Izumi, T., Mitra, S. & Tainer, J. A. DNA-bound structures and mutants reveal abasic DNA binding by APE1 DNA repair and coordination. Nature 403, 451-456 (2000). (Pubitemid 30073097)
27. Sieber, O. M. et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N. Engl. J. Med. 348, 791-799 (2003). (Pubitemid 36245755)
28. Fleischmann, C. et al. Comprehensive analysis of the contribution of germline MYH variation to early-onset colorectal cancer. Int. J. Cancer 109, 554-558 (2004). (Pubitemid 38339646)
29. Rusyn, I. et al. Transcriptional networks in S. cerevisiae linked to an accumulation of base excision repair intermediates. PLoS ONE 2, e1252 (2007).
30. Meira, L. B. et al. Aag-initiated base excision repair drives alkylation-induced retinal degeneration in mice. Proc. Natl Acad. Sci. USA 106, 888-893 (2009).
31. Sobol, R. W. et al. Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses. J. Biol. Chem. 278, 39951-39959 (2003).
32. Fishel, M. L., He, Y., Smith, M. L. & Kelley, M. R. Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Clin. Cancer Res. 13, 260-267 (2007). (Pubitemid 46121878)
33. Kaasen, I., Evensen, G. & Seeberg, E. Amplified expression of the tag+ and alkA+ genes in Escherichia coli: identification of gene products and effects on alkylation resistance. J. Bacteriol. 168, 642-647 (1986). (Pubitemid 17172750)
34. Xiao, W. & Samson, L. In vivo evidence for endogenous DNA alkylation damage as a source of spontaneous mutation in eukaryotic cells. Proc. Natl Acad. Sci. USA 90, 2117-2121 (1993). (Pubitemid 23078576)
35. Glassner, B. J., Rasmussen, L. J., Najarian, M. T., Posnick, L. M. & Samson, L. D. Generation of a strong mutator phenotype in yeast by imbalanced base excision repair. Proc. Natl Acad. Sci. USA 95, 9997-10002 (1998). (Pubitemid 28415283)
36. Posnick, L. M. & Samson, L. D. Imbalanced base excision repair increases spontaneous mutation and alkylation sensitivity in Escherichia coli. J. Bacteriol. 181, 6763-6771 (1999). (Pubitemid 29517992)
37. Calleja, F., Jansen, J. G., Vrieling, H., Laval, F. & van Zeeland, A. A. Modulation of the toxic and mutagenic effects induced by methyl methanesulfonate in Chinese hamster ovary cells by overexpression of the rat N-alkylpurine-DNA glycosylase. Mutat. Res. 425, 185-194 (1999). (Pubitemid 29182652)
38. Rinne, M., Caldwell, D. & Kelley, M. R. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol. Cancer Ther. 3, 955-967 (2004). (Pubitemid 39199590)
39. Rinne, M. L., He, Y., Pachkowski, B. F., Nakamura, J. & Kelley, M. R. N-methylpurine DNA glycosylase overexpression increases alkylation sensitivity by rapidly removing non-toxic 7-methylguanine adducts. Nucleic Acids Res. 33, 2859-2867 (2005). (Pubitemid 41511225)
40. Trivedi, R. N. et al. Human methyl purine DNA glycosylase and DNA polymerase β expression collectively predict sensitivity to temozolomide. Mol. Pharmacol. 74, 505-516 (2008).
41. Coquerelle, T., Dosch, J. & Kaina, B. Overexpression of N-methylpurine-DNA glycosylase in Chinese hamster ovary cells renders them more sensitive to the production of chromosomal aberrations by methylating agents-a case of imbalanced DNA repair. Mutat. Res. 336, 9-17 (1995).
42. Klapacz, J. et al. Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. Mol. Cell 37, 843-853 (2010).
43. Hofseth, L. J. et al. The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J. Clin. Invest. 112, 1887-1894 (2003). (Pubitemid 38063712)
44. Cerda, S. R., Turk, P. W., Thor, A. D. & Weitzman, S. A. Altered expression of the DNA repair protein, N-methylpurine-DNA glycosylase (MPG) in breast cancer. FEBS Lett. 431, 12-18 (1998). (Pubitemid 28330843)
45. Curtis, C. D., Thorngren, D. L. & Nardulli, A. M. Immunohistochemical analysis of oxidative stress and DNA repair proteins in normal mammary and breast cancer tissues. BMC Cancer 10, 9 (2010).
46. Kim, N. K. et al. Expression of the DNA repair enzyme, N-methylpurine-DNA glycosylase (MPG) in astrocytic tumors. Anticancer Res. 23, 1417-1423 (2003). (Pubitemid 36754109)
47. Mirabello, L. et al. A comprehensive candidate gene approach identifies genetic variation associated with osteosarcoma. BMC Cancer 11, 209 (2011).
48. Elder, R. H. et al. Alkylpurine-DNA-N-glycosylase knockout mice show increased susceptibility to induction of mutations by methyl methanesulfonate. Mol. Cell. Biol. 18, 5828-5837 (1998). (Pubitemid 28450534)
49. Engelward, B. P. et al. Base excision repair deficient mice lacking the Aag alkyladenine DNA glycosylase. Proc. Natl Acad. Sci. USA 94, 13087-13092 (1997). (Pubitemid 27518480)
50. Roth, R. B. & Samson, L. D. 3-Methyladenine DNA glycosylase-deficient Aag null mice display unexpected bone marrow alkylation resistance. Cancer Res. 62, 656-660 (2002). (Pubitemid 34126936)
51. Cardinal, J. W. et al. Increased susceptibility to streptozotocin-induced β-cell apoptosis and delayed autoimmune diabetes in alkylpurine-DNA-N- glycosylase-deficient mice. Mol. Cell. Biol. 21, 5605-5613 (2001). (Pubitemid 32702463)
52. Burns, N. & Gold, B. The effect of 3-methyladenine DNA glycosylase-mediated DNA repair on the induction of toxicity and diabetes by the β-cell toxicant streptozotocin. Toxicol. Sci. 95, 391-400 (2007). (Pubitemid 46152612)
53. Paik, J., Duncan, T., Lindahl, T. & Sedgwick, B. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. Cancer Res. 65, 10472-10477 (2005). (Pubitemid 41743742)
54. Engelward, B. P. et al. Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing. EMBO J. 15, 945-952 (1996). (Pubitemid 26064300)
55. Wirtz, S. et al. Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. Carcinogenesis 31, 2111-2117 (2010).
56. Meira, L. B. et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 118, 2516-2525 (2008). (Pubitemid 351949779)
57. Liu, L., Taverna, P., Whitacre, C. M., Chatterjee, S. & Gerson, S. L. Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and-proficient colon cancer cells to methylating agents. Clin. Cancer Res. 5, 2908-2917 (1999). (Pubitemid 29493970)
58. Loeb, L. A. & Preston, B. D. Mutagenesis by Apurinic/Apyrimidinic Sites. Annu. Rev. Genet. 20, 201-230 (1986).
59. Kunz, B. A. et al. Specificity of the mutator caused by deletion of the yeast structural gene (APN1) for the major apurinic endonuclease. Proc. Natl Acad. Sci. USA 91, 8165-8169 (1994). (Pubitemid 24253907)
60. Luo, M. & Kelley, M. R. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 24, 2127-2134 (2004). (Pubitemid 39166286)
61. Wang, D., Luo, M. & Kelley, M. R. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol. Cancer Ther. 3, 679-686 (2004). (Pubitemid 39193748)
62. Taverna, P. et al. Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat. Res. 485, 269-281 (2001). (Pubitemid 32406283)
63. Wilson, D. & Simeonov, A. Small molecule inhibitors of DNA repair nuclease activities of APE1. Cell. Mol. Life Sci. 67, 3621-3631 (2010).
64. Sobol, R. W. et al. Requirement of mammalian DNA polymerase-β in base-excision repair. Nature 379, 183-186 (1996). (Pubitemid 26020204)
65. Cabelof, D. C. et al. Base excision repair deficiency caused by polymerase β haploinsufficiency: accelerated DNA damage and increased mutational response to carcinogens. Cancer Res. 63, 5799-5807 (2003). (Pubitemid 37187477)
66. Sobol, R. W. et al. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc. Natl Acad. Sci. USA 99, 6860-6865 (2002). (Pubitemid 34526223)
67. Poltoratsky, V., Horton, J. K., Prasad, R. & Wilson, S. H. REV1 mediated mutagenesis in base excision repair deficient mouse fibroblast. DNA Repair 4, 1182-1188 (2005). (Pubitemid 41316595)
68. Horton, J. K., Joyce-Gray, D. F., Pachkowski, B. F., Swenberg, J. A. & Wilson, S. H. Hypersensitivity of DNA polymerase β null mouse fibroblasts reflects accumulation of cytotoxic repair intermediates from site-specific alkyl DNA lesions. DNA Repair 2, 27-48 (2003). (Pubitemid 35435437)
69. Sobol, R. W. et al. The lyase activity of the DNA repair protein β-polymerase protects from DNA-damage-induced cytotoxicity. Nature 405, 807-810 (2000). (Pubitemid 30407855)
70. Wang, L., Bhattacharyya, N., Rabi, T. & Banerjee, S. Mammary carcinogenesis in transgenic mice expressing a dominant-negative mutant of DNA polymerase β in their mammary glands. Carcinogenesis 28, 1356-1363 (2007). (Pubitemid 47062697)
71. Chan, K. et al. Overexpression of DNA polymerase β results in an increased rate of frameshift mutations during base excision repair. Mutagenesis 22, 183-188 (2007). (Pubitemid 47355706)
72. Yamada, N. A. & Farber, R. A. Induction of a low level of microsatellite instability by overexpression of DNA polymerase β. Cancer Res. 62, 6061-6064 (2002). (Pubitemid 35244453)
73. Almeida, K. H. & Sobol, R. W. A unified view of base excision repair: lesion-dependent protein complexes regulated by post-translational modification. DNA Repair 6, 695-711 (2007). (Pubitemid 46670095)
74. Ström, C. E. et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 39, 3166-3175 (2010).
75. Zdzienicka, M. Z. et al. A Chinese hamster ovary cell mutant (EM-C11) with sensitivity to simple alkylating agents and a very high level of sister chromatid exchanges. Mutagenesis 7, 265-269 (1999).
76. Horton, J. K. et al. XRCC1 and DNA polymerase β in cellular protection against cytotoxic DNA single-strand breaks. Cell Res. 18, 48-63 (2008).
77. Briegert, M. & Kaina, B. Human monocytes, but not dendritic cells derived from them, are defective in base excision repair and hypersensitive to methylating agents. Cancer Res. 67, 26-31 (2007). (Pubitemid 46142756)
78. Jiang, Y., Zhou, S., Sandusky, G. E., Kelley, M. R. & Fishel, M. L. Reduced expression of DNA repair and redox signaling protein APE1/Ref-1 impairs human pancreatic cancer cell survival, proliferation, and cell cycle progression. Cancer Invest. 28, 885-895 (2010).
79. Al-Attar, A. et al. Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. Br. J. Cancer 102, 704-709 (2010).
80. Di Maso, V. et al. Subcellular localization of APE1/Ref-1 in human hepatocellular carcinoma: possible prognostic significance. Mol. Med. 13, 89-96 (2007). (Pubitemid 46786837)
81. Freitas, S., Moore, D. H., Michael, H. & Kelley, M. R. Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer. Clin. Cancer Res. 9, 4689-4694 (2003).
82. Kakolyris, S. et al. Nuclear localization of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early operable non-small cell lung cancer (NSCLC). The J. Pathol. 189, 351-357 (1999). (Pubitemid 29489219)
83. Sweasy, J. B., Lang, T. & DiMaio, D. Is base excision repair a tumor suppressor mechanism? Cell Cycle 5, 250-259 (2006). (Pubitemid 43213493)
84. Starcevic, D., Dalal, S. & Sweasy, J. B. Is there a link between DNA polymerase β and cancer? Cell Cycle 3, 996-999 (2004).
85. Jiang, J., Zhang, X., Yang, H. & Wang, W. Polymorphisms of DNA repair genes: ADPRT, XRCC1, and XPD and cancer risk in genetic epidemiology. Methods Mol. Biol. 471, 305-333 (2009).
86. Simeonov, A. et al. Identification and characterization of inhibitors of human apurinic/apyrimidinic endonuclease APE1. PLoS ONE 4, e5740 (2009).
87. Bapat, A. et al. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J. Pharmacol. Exp. Ther. 334, 988-998 (2010).
88. Tang, J.-b. et al. N-methylpurine DNA glycosylase and DNA polymerase β modulate BER inhibitor potentiation of glioma cells to temozolomide. Neuro Oncol. 13, 471-486 (2011).
89. Liu, L. & Gerson, S. L. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623-627 (2004).
90. Jiang, Y. et al. Role of APE1 in differentiated neuroblastoma SH-SY5Y cells in response to oxidative stress: use of APE1 small molecule inhibitors to delineate APE1 functions. DNA Repair 8, 1273-1282 (2009).
91. Izumi, T. et al. Two essential but distinct functions of the mammalian abasic endonuclease. Proc. Natl Acad. Sci. USA 102, 5739-5743 (2005). (Pubitemid 40559629)
92. Wilson, S. et al. Base excision repair and design of small molecule inhibitors of human DNA polymerase β. Cell. Mol. Life Sci. 67, 3633-3647 (2010).
93. Hu, H. Y. et al. Identification of small molecule synthetic inhibitors of DNA polymerase β by NMR chemical shift mapping. J. Biol. Chem. 279, 39736-39744 (2004).
94. Jaiswal, A. S. et al. A novel inhibitor of DNA polymerase β enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol. Cancer Res. 7, 1973-1983 (2009).
95. Jaiswal, A. S. et al. DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS ONE 6, e16691 (2011).
96. Stachelek, G. C. et al. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase β is accentuated by BRCA2 mutation. Cancer Res. 70, 409-417 (2010).
97. Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H. & Poirier, G. G. PARP inhibition: PARP1 and beyond. Nature Rev. Cancer 10, 293-301 (2010).
98. Mégnin-Chanet, F., Bollet, M. & Hall, J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell. Mol. Life Sci. 67, 3649-3662 (2010).
99. de Murcia, J. M. et al. Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl Acad. Sci. USA 94, 7303-7307 (1997).
100. Shibata, A. et al. Parp-1 deficiency causes an increase of deletion mutations and insertions/rearrangements in vivo after treatment with an alkylating agent. Oncogene 24, 1328-1337 (2005). (Pubitemid 40343113)
101. Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913-917 (2005). (Pubitemid 40559005)
102. Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
103. Jelezcova, E. et al. Parp1 activation in mouse embryonic fibroblasts promotes Pol β-dependent cellular hypersensitivity to alkylation damage. Mutat. Res. 686, 57-67 (2010).
104. Kelley, M. R. DNA repair inhibitors: where do we go from here? DNA Repair 10, 1183-1185 (2011).
105. Pegg, A. E. Multifaceted roles of alkyltransferase and related proteins in DNA repair, DNA damage, resistance to chemotherapy, and research tools. Chem. Res. Toxicol. 24, 618-639 (2011).
106. Nakatsuru, Y. et al. O6-methylguanine-DNA methyltransferase protects against nitrosamine-induced hepatocarcinogenesis. Proc. Natl Acad. Sci. USA 90, 6468-6472 (1993). (Pubitemid 23207234)
107. Dumenco, L. L., Allay, E., Norton, K. & Gerson, S. L. The prevention of thymic lymphomas in transgenic mice by human O6-alkylguanine-DNA alkyltransferase. Science 259, 219-222 (1993). (Pubitemid 23041797)
108. Liu, L., Allay, E., Dumenco, L. L. & Gerson, S. L. Rapid repair of O6-methylguanine-DNA adducts protects transgenic mice from N-methylnitrosourea- induced thymic lymphomas. Cancer Res. 54, 4648-4652 (1994).
109. Allay, E., Veigl, M. & Gerson, S. L. Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea. Oncogene 18, 3783-3787 (1999). (Pubitemid 29338512)
110. Zhou, Z. Q. et al. Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6-methylguanine-DNA methyltransferase. Proc. Natl Acad. Sci. USA 98, 12566-12571 (2001).
111. Zaidi, N. H. et al. Transgenic expression of human MGMT protects against azoxymethane-induced aberrant crypt foci and G to A mutations in the K-ras oncogene of mouse colon. Carcinogenesis 16, 451-456 (1995).
112. Becker, K., Dosch, J., Gregel, C. M., Martin, B. A. & Kaina, B. Targeted expression of human O6-methylguanine-DNA methyltransferase (MGMT) in transgenic mice protects against tumor initiation in two-stage skin carcinogenesis. Cancer Res. 56, 3244-3249 (1996). (Pubitemid 26242971)
113. Becker, K. et al. DNA repair protein MGMT protects against N-methyl-N-nitrosourea-induced conversion of benign into malignant tumors. Carcinogenesis 24, 541-546 (2003). (Pubitemid 36432651)
114. Becker, K., Gregel, C. M. & Kaina, B. The DNA repair protein O6-methylguanine-DNA methyltransferase protects against skin tumor formation induced by antineoplastic chloroethylnitrosourea. Cancer Res. 57, 3335-3338 (1997). (Pubitemid 27355469)
115. Allay, E. et al. Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O6-alkylguanine DNA-alkyltransferase. Oncogene 15, 2127-2132 (1997). (Pubitemid 27489139)
116. Qin, X., Zhou, H., Liu, L. & Gerson, S. L. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis. Carcinogenesis 20, 1667-1673 (1999). (Pubitemid 29410543)
117. Qin, X., Liu, L. & Gerson, S. L. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT. Oncogene 18, 4394-4400 (1999). (Pubitemid 29392381)
118. Reese, J. S., Allay, E. & Gerson, S. L. Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice. Oncogene 20, 5258-5263 (2001). (Pubitemid 32844058)
119. Kisby, G. E. et al. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair 8, 400-412 (2009).
120. Tsuzuki, T. et al. Targeted disruption of the DNA repair methyltransferase gene renders mice hypersensitive to alkylating agent. Carcinogenesis 17, 1215-1220 (1996). (Pubitemid 26196331)
121. Glassner, B. J. et al. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents. Mutagenesis 14, 339-347 (1999). (Pubitemid 29219020)
122. Klapacz, J. et al. O6-methylguanine-induced cell death involves exonuclease 1 as well as DNA mismatch recognition in vivo. Proc. Natl Acad. Sci. USA 106, 576-581 (2009).
123. Reese, J. S., Qin, X., Ballas, C. B., Sekiguchi, M. & Gerson, S. L. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure. J. Hematother. Stem Cell Res. 10, 115-123 (2001). (Pubitemid 32233697)
124. Sakumi, K. et al. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice. Cancer Res. 57, 2415-2418 (1997). (Pubitemid 27255900)
125. Iwakuma, T. et al. High incidence of nitrosamine-induced tumorigenesis in mice lacking DNA repair methyltransferase. Carcinogenesis 18, 1631-1635 (1997). (Pubitemid 28134789)
126. Hansen, R. J., Nagasubramanian, R., Delaney, S. M., Samson, L. D. & Dolan, M. E. Role of O6-methylguanine-DNA methyltransferase in protecting from alkylating agent-induced toxicity and mutations in mice. Carcinogenesis 28, 1111-1116 (2007). (Pubitemid 47072198)
127. Christmann, M., Verbeek, B., Roos, W. P. & Kaina, B. O6-Methylguanine-DNA methyltransferase (MGMT) in normal tissues and tumors: enzyme activity, promoter methylation and immunohistochemistry. Biochim. Biophys. Acta 1816, 179-190 (2011).
128. Hongeng, S. et al. O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. Clin. Cancer Res. 3, 2459-2463 (1997). (Pubitemid 28133168)
129. Bobola, M. S. et al. O6-methylguanine-DNA methyltransferase in pediatric primary brain tumors. Clin. Cancer Res. 7, 613-619 (2001).
130. Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997-1003 (2005). (Pubitemid 40349502)
131. Christmann, M. et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma. Int. J. Cancer 127, 2106-2118 (2010).
132. Kaina, B., Margison, G. & Christmann, M. Targeting O6-methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 67, 3663-3681 (2010).
133. Weingart, J. et al. Phase I trial of polifeprosan 20 with carmustine implant plus continuous infusion of intravenous O6-benzylguanine in adults with recurrent malignant glioma: new approaches to brain tumor therapy CNS consortium trial. J. Clin. Oncol. 25, 399-404 (2007). (Pubitemid 350002988)
134. Quinn, J. A. et al. Phase II trial of temozolomide plus O6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J. Clin. Oncol. 27, 1262-1267 (2009).
135. Batts, E. et al. O6-benzylguanine and BCNU in multiple myeloma: a phase II trial. Cancer Chemother. Pharmacol. 60, 415-421 (2007). (Pubitemid 46944590)
136. Gajewski, T. F. et al. Phase II trial of the O6-alkylguanine DNA alkyltransferase inhibitor O6-benzylguanine and 1,3-bis(2-chloroethyl)-1- nitrosourea in advanced melanoma. Clin. Cancer Res. 11, 7861-7865 (2005). (Pubitemid 41611631)
137. Moritz, T., Mackay, W., Glassner, B. J., Williams, D. A. & Samson, L. Retrovirus-mediated expression of a DNA repair protein in bone marrow protects hematopoietic cells from nitrosourea-induced toxicity in vitro and in vivo. Cancer Res. 55, 2608-2614 (1995).
138. Maze, R. et al. Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. Proc. Natl Acad. Sci. USA 93, 206-210 (1996).
139. Jelinek, J. et al. Long-term protection of hematopoiesis against the cytotoxic effects of multiple doses of nitrosourea by retrovirus-mediated expression of human O6-alkylguanine-DNA-alkyltransferase. Blood 87, 1957-1961 (1996).
140. Allay, J. A., Koç, O. N., Davis, B. M. & Gerson, S. L. Retroviral-mediated gene transduction of human alkyltransferase complementary DNA confers nitrosourea resistance to human hematopoietic progenitors. Clin. Cancer Res. 2, 1353-1359 (1996). (Pubitemid 26299434)
141. Schambach, A. & Baum, C. Vector design for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells. DNA Repair 6, 1187-1196 (2007). (Pubitemid 47058401)
142. Neff, T. et al. Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. J. Clin. Invest. 112, 1581-1588 (2003). (Pubitemid 38056284)
143. Maze, R., Hanenberg, H. & Williams, D. A. Establishing chemoresistance in hematopoietic progenitor cells. Mol. Med. Today 3, 350-358 (1997). (Pubitemid 28119270)
144. Ragg, S., Xu-Welliver, M. & Bailey, J. Direct reversal of DNA damage by mutant methyltransferase protein protects mice against dose-intensified chemotherapy and leads to in vivo selection of hematopoietic stem cells. Cancer Res. 60, 5187-5195 (2000).
145. Jansen, M. et al. Hematoprotection and enrichment of transduced cells in vivo after gene transfer of MGMTP140K into hematopoietic stem cells. Cancer Gene Ther. 9, 737-746 (2002). (Pubitemid 34971304)
146. Neff, T. et al. Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. Blood 105, 997-1002 (2005). (Pubitemid 40170867)
147. Reha-Krantz, L. J., Nonay, R. L., Day, R. S. & Wilson, S. H. Replication of O6-methylguanine-containing DNA by repair and replicative DNA polymerases. J. Biol. Chem. 271, 20088-20095 (1996). (Pubitemid 26281760)
148. Haracska, L., Prakash, S. & Prakash, L. Replication past O6-methylguanine by yeast and human DNA polymerase eta. Mol. Cell. Biol. 20, 8001-8007 (2000).
149. Choi, J. Y. et al. Translesion synthesis across O6-alkylguanine DNA adducts by recombinant human DNA polymerases. J. Biol. Chem. 281, 38244-38256 (2006).
150. Takenaka, K. et al. Involvement of vertebrate Polκ in translesion DNA synthesis across DNA monoalkylation damage. J. Biol. Chem. 281, 2000-2004 (2006). (Pubitemid 43845787)
151. Haracska, L., Prakash, S. & Prakash, L. Yeast DNA polymerase ζ is an efficient extender of primer ends opposite from 7,8-dihydro-8-oxoguanine and O6-methylguanine. Mol. Cell. Biol. 23, 1453-1459 (2003). (Pubitemid 36177052)
152. Haracska, L., Prakash, L. & Prakash, S. Role of human DNA polymerase κ as an extender in translesion synthesis. Proc. Natl Acad. Sci. USA 99, 16000-16005 (2002). (Pubitemid 35462738)
153. Kaina, B., Gerhard, F., Sankar, M. & Coquerelle, T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic
154. Lips, J. & Kaina, B. Repair of O6-methylguanine is not affected by thymine base pairing and the presence of MMR proteins. DNA Repair 487, 59-66 (2001). (Pubitemid 32947065)
155. Casorelli I, Russo MT & M., B. Role of mismatch repair and MGMT in response to anticancer therapies. Anticancer Agents Med. Chem. 8, 368-380 (2008). (Pubitemid 351761422)
156. Duckett, D. R. et al. Human MutSα recognizes damaged DNA base pairs containing O6-methylguanine, O4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl Acad. Sci. USA 93, 6443-6447 (1996).
157. Meikrantz, W., Bergom, M. A., Memisoglu, A. & Samson, L. O6-alkylguanine DNA lesions trigger apoptosis. Carcinogenesis 19, 369-372 (1998). (Pubitemid 28375435)
158. Rasmussen, L. J. & Samson, L. The Escherichia coli MutS DNA mismatch binding protein specifically binds O6-methylguanine DNA lesions. Carcinogenesis 17, 2085-2088 (1996). (Pubitemid 26325409)
159. Dosch, J., Christmann, M. & Kaina, B. Mismatch G-T binding activity and MSH2 expression is quantitatively related to sensitivity of cells to methylating agents. Carcinogenesis 19, 567-573 (1998). (Pubitemid 28376798)
160. Hickman, M. J. & Samson, L. D. Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents. Proc. Natl Acad. Sci. USA 96, 10764-10769 (1999). (Pubitemid 29442218)
161. Mojas, N., Lopes, M. & Jiricny, J. Mismatch repair-dependent processing of methylation damage gives rise to persistent single-stranded gaps in newly replicated DNA. Genes Dev. 21, 3342-3355 (2007). (Pubitemid 350277760)
162. Ochs, K. & Kaina, B. Apoptosis induced by DNA damage O6-methylguanine is Bcl-2 and caspase-9/3 regulated and Fas/caspase-8 independent. Cancer Res. 60, 5815-5824 (2000).
163. Rajesh, P., Rajesh, C., Wyatt, M. D. & Pittman, D. L. RAD51D protects against MLH1-dependent cytotoxic responses to O6-methylguanine. DNA Repair 9, 458-467 (2010).
164. Roos, W. P. et al. Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O6-methylguanine triggered apoptosis, DSBs and chromosomal aberrations by a process leading to SCEs. DNA Repair 8, 72-86 (2009).
165. Cejka, P. & Jiricny, J. Interplay of DNA repair pathways controls methylation damage toxicity in saccharomyces cerevisiae. Genetics 179, 1835-1844 (2008).
166. Mirzoeva, O. K., Kawaguchi, T. & Pieper, R. O. The Mre11/Rad50/Nbs1 complex interacts with the mismatch repair system and contributes to temozolomide-induced G2 arrest and cytotoxicity. Mol. Cancer Ther. 5, 2757-2766 (2006). (Pubitemid 44849002)
167. Tsaryk, R., Fabian, K., Thacker, J. & Kaina, B. Xrcc2 deficiency sensitizes cells to apoptosis by MNNG and the alkylating anticancer drugs temozolomide, fotemustine and mafosfamide. Cancer Lett. 239, 305-313 (2006). (Pubitemid 43977859)
168. Eich, M., Roos, W. P., Dianov, G. L., Digweed, M. & Kaina, B. Nijmegen breakage syndrome protein (NBN) causes resistance to methylating anticancer drugs such as temozolomide. Mol. Pharmacol. 78, 943-951 (2010).
169. Kaina, B. The interrelationship between SCE induction, cell survival, mutagenesis, aberration formation and DNA synthesis inhibition in V79 cells treated with N-methyl-N-nitrosourea or N-methyl-N'-nitro-N-nitrosoguanidine. Mutat. Res. 142, 49-54 (1985). (Pubitemid 15162229)
170. Yoshioka, K.-i., Yoshioka, Y. & Hsieh, P. ATR kinase activation mediated by MutSα and MutLα in response to cytotoxic O6-methylguanine adducts. Mol. Cell 22, 501-510 (2006).
171. Branch, P., Aquilina, G., Bignami, M. & Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362, 652-654 (1993). (Pubitemid 23109278)
172. Koi, M. et al. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res. 54, 4308-4312 (1994).
173. de Wind, N., Dekker, M., Berns, A., Radman, M. & te Riele, H. Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. Cell 82, 321-330 (1995).
174. Andrew, S. E. et al. Tissues of MSH2-deficient mice demonstrate hypermutability on exposure to a DNA methylating agent. Proc. Natl Acad. Sci. USA 95, 1126-1130 (1998). (Pubitemid 28124923)
175. Hickman, M. J. & Samson, L. D. Apoptotic signaling in response to a single type of DNA lesion, O6-methylguanine. Mol. Cell 14, 105-116 (2004). (Pubitemid 38469913)
176. Toft, N. J. et al. Msh2 status modulates both apoptosis and mutation frequency in the murine small intestine. Proc. Natl Acad. Sci. USA 96, 3911-3915 (1999). (Pubitemid 29169010)
177. Sansom, O. J., Toft, N. J., Winton, D. J. & Clarke, A. R. Msh-2 suppresses in vivo mutation in a gene dose and lesion dependent manner. Oncogene 20, 3580-3584 (2001). (Pubitemid 32619412)
178. Sansom, O. J. & Clarke, A. R. The ability to engage enterocyte apoptosis does not predict long-term crypt survival in p53 and Msh2 deficient mice. Oncogene 21, 5934-5939 (2002). (Pubitemid 35007245)
179. Reese, J. S., Liu, L. & Gerson, S. L. Repopulating defect of mismatch repair-deficient hematopoietic stem cells. Blood 102, 1626-1633 (2003). (Pubitemid 37022553)
180. Sansom, O. J. et al. Apoptosis and mutation in the murine small intestine: loss of Mlh1-and Pms2-dependent apoptosis leads to increased mutation in vivo. DNA Repair 2, 1029-1039 (2003). (Pubitemid 37098296)
181. Bugni, J. M., Meira, L. B. & Samson, L. D. Alkylation-induced colon tumorigenesis in mice deficient in the Mgmt and Msh6 proteins. Oncogene 28, 734-741 (2009).
182. Kawate, H. et al. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice. Carcinogenesis 21, 301-305 (2000). (Pubitemid 30098717)
183. Stallons, L. J. & McGregor, W. G. Translesion synthesis polymerases in the prevention and promotion of carcinogenesis. J. Nucleic Acids 2010, 1-10 (2010).
184. Moynahan, M. E. & Jasin, M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nature Rev. Mol. Cell Biol. 11, 196-207 (2010).
185. Arana, M. E. & Kunkel, T. A. Mutator phenotypes due to DNA replication infidelity. Semin. Cancer Biol. 20, 304-311 (2010).
186. Hewish, M., Lord, C. J., Martin, S. A., Cunningham, D. & Ashworth, A. Mismatch repair deficient colorectal cancer in the era of personalized treatment. Nature Rev. Clin. Oncol. 7, 197-208 (2010).
187. Trainer, A. H. et al. The role of BRCA mutation testing in determining breast cancer therapy. Nature Rev. Clin. Oncol. 7, 708-717 (2010).
188. Valeri, N. et al. Modulation of mismatch repair and genomic stability by miR-155. Proc. Natl Acad. Sci. USA 107, 6982-6987 (2010).
189. Moskwa, P. et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol. Cell 41, 210-220 (2011).
190. Kiltie, A. E. (ed.) Molecular Epidemiology of DNA Repair Genes in Bladder Cancer (Humana Press, Bethesda, 2009).
191. Fenske, T. S. et al. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res. 66, 5029-5038 (2006). (Pubitemid 43844923)
192. Lutz, W. A true threshold dose in chemical carcinogenesis cannot be defined for a population, irrespective of the mode of action. Hum. Exp. Toxicol. 19, 566-568 (2000). (Pubitemid 32117867)
193. Fry, R. C. et al. Genomic predictors of interindividual differences in response to DNA damaging agents. Genes Dev. 22, 2621-2626 (2008).
194. Begley, T. J., Rosenbach, A. S., Ideker, T. & Samson, L. D. Hot spots for modulating toxicity identified by genomic phenotyping and localization mapping. Mol. Cell 16, 117-125 (2004). (Pubitemid 39330157)
195. Ravi, D. et al. A network of conserved damage survival pathways revealed by a genomic RNAi screen. PLoS Genet. 5, e1000527 (2009).
196. McKinnon, P. J. DNA repair deficiency and neurological disease. Nature Rev. Neurosci. 10, 100-112 (2009).
197. Robbins JH, Kraemer KH, Lutzner MA, Festoff BW & HG., C. Xeroderma pigmentosum. An inherited diseases with sun sensitivity, multiple cutaneous neoplasms, and abnormal DNA repair. Ann. Intern. Med. 80, 221-248 (1974).
198. Savitsky, K. et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science 268, 1749-1753 (1995).
199. Lovell, M. A., Xie, C. & Markesbery, W. R. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain. Brain Res. 855, 116-123 (2000). (Pubitemid 30067701)
200. Weissman, L., de Souza-Pinto, N. C., Mattson, M. P. & Bohr, V. A. DNA base excision repair activities in mouse models of Alzheimer's disease. Neurobiol. Aging 30, 2080-2081 (2009).
201. Iida, T., Furuta, A., Nishioka, K., Nakabeppu, Y. & Iwaki, T. Expression of 8-oxoguanine DNA glycosylase is reduced and associated with neurofibrillary tangles in Alzheimer's disease brain. Acta Neuropathol. 103, 20-25 (2002). (Pubitemid 36075308)
202. Weissman, L. et al. Defective DNA base excision repair in brain from individuals with Alzheimer's disease and amnestic mild cognitive impairment. Nucleic Acids Res. 35, 5545-5555 (2007). (Pubitemid 47423927)
203. Hegde, M. L., Hazra, T. K. & Mitra, S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 18, 27-47 (2008).
204. Zecca, L., Youdim, M. B. H., Riederer, P., Connor, J. R. & Crichton, R. R. Iron, brain ageing and neurodegenerative disorders. Nature Rev. Neurosci. 5, 863-873 (2004). (Pubitemid 39482155)
205. Interthal, H. et al. SCAN1 mutant Tdp1 accumulates the enzyme-DNA intermediate and causes camptothecin hypersensitivity. EMBO J. 24, 2224-2233 (2005). (Pubitemid 40961806)
206. El-Khamisy, S. F. et al. Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1. Nature 434, 108-113 (2005). (Pubitemid 40349394)
207. Lee, Y. et al. The genesis of cerebellar interneurons and the prevention of neural DNA damage require XRCC1. Nature Neurosci. 12, 973-980 (2009).
208. Lauritzen, K. H. et al. Mitochondrial DNA toxicity in forebrain neurons causes apoptosis, neurodegeneration, and impaired behavior. Mol. Cell. Biol. 30, 1357-1367 (2010).
209. Liu, L., Qin, X. & Gerson, S.L. Reduced lung tumorigenesis in human methylguanine DNA-methyltransferase transgenic mice achieved by expression of transgene within target cell. Carcinogenesis 20, 279-284 (1999). (Pubitemid 29057561)